{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:01:30Z","timestamp":1791054090163,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007109","name":"Universit\u00e0 degli Studi di Ferrara","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Purinergic Signalling"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>ATP is a ubiquitous extracellular messenger released in a wide number of pathophysiological conditions. ATP is known to be present in minute amounts in the extracellular space in healthy tissues and in the blood, and to modulate a multiplicity of cell responses. Cell culture systems are widely used to explore purinergic signaling. We show here that currently used fetal bovine sera contain ATP in the 300\u20131300\u00a0pmol\/L range. Serum ATP is associated with albumin as well as with microparticle\/microvesicle fraction. Serum microparticles\/microvesicles affect in vitro cell responses due to their content of miRNAs, growth factors, and other bioactive molecules. ATP is likely to be one of these bioactive factors found in a variable amount in sera of different commercial sources. ATP in serum supports ATP-dependent biochemical reactions such as the hexokinase-dependent phosphorylation of glucose to glucose 6-phosphate, and affects purinergic signaling. These findings show that cells growing in vitro in serum-supplemented media are exposed to varying levels of extracellular ATP, and thus to varying degrees of purinergic stimulation.\n<\/jats:p>","DOI":"10.1007\/s11302-023-09941-2","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T04:13:09Z","timestamp":1681877589000},"page":"83-89","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Fetal bovine serum contains biologically available ATP"],"prefix":"10.1007","volume":"20","author":[{"given":"Valentina","family":"Vultaggio-Poma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Scussel Bergamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Falzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Tarantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Lisa","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorianna","family":"Sandon\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Polverino De Laureto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Virgilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"issue":"2","key":"9941_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/026119290203000208","volume":"30","author":"CE Jochems","year":"2002","unstructured":"Jochems CE, van der Valk JB, Stafleu FR, Baumans V (2002) The use of fetal bovine serum: ethical or scientific problem? Altern Lab Anim 30(2):219\u2013227. https:\/\/doi.org\/10.1177\/026119290203000208","journal-title":"Altern Lab Anim"},{"key":"9941_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fimmu.2019.00012","volume":"10","author":"E Neubert","year":"2019","unstructured":"Neubert E, Senger-Sander SN, Manzke VS, Busse J, Polo E, Scheidmann SEF, Schon MP, Kruss S, Erpenbeck L (2019) Serum and serum albumin inhibit in vitro formation of neutrophil extracellular traps (NETs). Front Immunol 10:12. https:\/\/doi.org\/10.3389\/fimmu.2019.00012","journal-title":"Front Immunol"},{"issue":"1","key":"9941_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00418-021-01981-2","volume":"156","author":"C Bernardini","year":"2021","unstructured":"Bernardini C, Algieri C, Mantia D, Zannoni A, Salaroli R, Trombetti F, Forni M, Pagliarani A, Nesci S (2021) Relationship between serum concentration, functional parameters and cell bioenergetics in IPEC-J2 cell line. Histochem Cell Biol 156(1):59\u201367. https:\/\/doi.org\/10.1007\/s00418-021-01981-2","journal-title":"Histochem Cell Biol"},{"issue":"3","key":"9941_CR4","doi-asserted-by":"publisher","first-page":"e12061","DOI":"10.1002\/jev2.12061","volume":"10","author":"BM Lehrich","year":"2021","unstructured":"Lehrich BM, Liang Y, Fiandaca MS (2021) Foetal bovine serum influence on in vitro extracellular vesicle analyses. J Extracell Vesicles 10(3):e12061. https:\/\/doi.org\/10.1002\/jev2.12061","journal-title":"J Extracell Vesicles"},{"issue":"1","key":"9941_CR5","doi-asserted-by":"publisher","first-page":"1535750","DOI":"10.1080\/20013078.2018.1535750","volume":"7","author":"C Thery","year":"2018","unstructured":"Thery C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R et al (2018) Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 7(1):1535750. https:\/\/doi.org\/10.1080\/20013078.2018.1535750","journal-title":"J Extracell Vesicles"},{"key":"9941_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12896-016-0262-0","volume":"16","author":"H Aswad","year":"2016","unstructured":"Aswad H, Jalabert A, Rome S (2016) Depleting extracellular vesicles from fetal bovine serum alters proliferation and differentiation of skeletal muscle cells in vitro. BMC Biotechnol 16:32. https:\/\/doi.org\/10.1186\/s12896-016-0262-0","journal-title":"BMC Biotechnol"},{"issue":"11","key":"9941_CR7","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.yexcr.2009.03.010","volume":"315","author":"J Ochieng","year":"2009","unstructured":"Ochieng J, Pratap S, Khatua AK, Sakwe AM (2009) Anchorage-independent growth of breast carcinoma cells is mediated by serum exosomes. Exp Cell Res 315(11):1875\u20131888. https:\/\/doi.org\/10.1016\/j.yexcr.2009.03.010","journal-title":"Exp Cell Res"},{"key":"9941_CR8","doi-asserted-by":"publisher","unstructured":"Shelke GV, Lasser C, Gho YS, Lotvall J (2014) Importance of exosome depletion protocols to eliminate functional and RNA-containing extracellular vesicles from fetal bovine serum. J Extracell Vesicles 3:24783. https:\/\/doi.org\/10.3402\/jev.v3.24783","DOI":"10.3402\/jev.v3.24783"},{"key":"9941_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.diff.2020.06.004","volume":"115","author":"Q Zhou","year":"2020","unstructured":"Zhou Q, Xie F, Zhou B, Li C, Kang Y, Wu B, Li L, Dai R (2020) Fetal bovine serum-derived exosomes regulate the adipogenic differentiation of human bone marrow mesenchymal stromal cells in a cross-species manner. Differentiation 115:11\u201321. https:\/\/doi.org\/10.1016\/j.diff.2020.06.004","journal-title":"Differentiation"},{"issue":"2","key":"9941_CR10","doi-asserted-by":"publisher","first-page":"859","DOI":"10.7150\/thno.66274","volume":"12","author":"V Vultaggio-Poma","year":"2022","unstructured":"Vultaggio-Poma V, Falzoni S, Chiozzi P, Sarti AC, Adinolfi E, Giuliani AL, Sanchez-Melgar A, Boldrini P, Zanoni M, Tesei A, Pinton P, Di Virgilio F (2022) Extracellular ATP is increased by release of ATP-loaded microparticles triggered by nutrient deprivation. Theranostics 12(2):859\u2013874. https:\/\/doi.org\/10.7150\/thno.66274","journal-title":"Theranostics"},{"issue":"3","key":"9941_CR11","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/0014-5793(92)81211-4","volume":"313","author":"M Bauer","year":"1992","unstructured":"Bauer M, Baumann J, Trommer WE (1992) ATP binding to bovine serum albumin. FEBS Lett 313(3):288\u2013290. https:\/\/doi.org\/10.1016\/0014-5793(92)81211-4","journal-title":"FEBS Lett"},{"issue":"2\u20133","key":"9941_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/s0301-4622(97)00084-7","volume":"69","author":"S Takeda","year":"1997","unstructured":"Takeda S, Miyauchi S, Nakayama H, Kamo N (1997) Adenosine 5\u2032-triphosphate binding to bovine serum albumin. Biophys Chem 69(2\u20133):175\u2013183. https:\/\/doi.org\/10.1016\/s0301-4622(97)00084-7","journal-title":"Biophys Chem"},{"issue":"7","key":"9941_CR13","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/sj.bjp.0703968","volume":"132","author":"AD Michel","year":"2001","unstructured":"Michel AD, Xing M, Humphrey PP (2001) Serum constituents can affect 2\u2032-& 3\u2032-O-(4-benzoylbenzoyl)-ATP potency at P2X(7) receptors. Br J Pharmacol 132(7):1501\u20131508. https:\/\/doi.org\/10.1038\/sj.bjp.0703968","journal-title":"Br J Pharmacol"},{"issue":"6","key":"9941_CR14","first-page":"735","volume":"50","author":"VA Gaevskaia","year":"1978","unstructured":"Gaevskaia VA,\u00a0Azhitskii G (1978) [Isoelectric fractions of healthy human serum albumin and their ability to bind bilirubin]. Ukr Biokhim Zh 50(6):735\u2013738","journal-title":"Ukr Biokhim Zh"},{"key":"9941_CR15","doi-asserted-by":"publisher","first-page":"239821281881749","DOI":"10.1177\/2398212818817494","volume":"2","author":"G Burnstock","year":"2018","unstructured":"Burnstock G (2018) Purine and purinergic receptors. Brain Neurosci Adv 2:2398212818817494. https:\/\/doi.org\/10.1177\/2398212818817494","journal-title":"Brain Neurosci Adv"},{"key":"9941_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.imlet.2018.11.006","volume":"205","author":"AL Giuliani","year":"2019","unstructured":"Giuliani AL, Sarti AC, Di Virgilio F (2019) Extracellular nucleotides and nucleosides as signalling molecules. Immunol Lett 205:16\u201324. https:\/\/doi.org\/10.1016\/j.imlet.2018.11.006","journal-title":"Immunol Lett"},{"issue":"3","key":"9941_CR17","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1124\/pr.58.3.3","volume":"58","author":"MP Abbracchio","year":"2006","unstructured":"Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Knight GE, Fumagalli M, Gachet C, Jacobson KA, Weisman GA (2006) International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 58(3):281\u2013341. https:\/\/doi.org\/10.1124\/pr.58.3.3","journal-title":"Pharmacol Rev"},{"issue":"3","key":"9941_CR18","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/bph.15299","volume":"178","author":"P Illes","year":"2021","unstructured":"Illes P, Muller CE, Jacobson KA, Grutter T, Nicke A, Fountain SJ, Kennedy C, Schmalzing G, Jarvis MF, Stojilkovic SS, King BF, Di Virgilio F (2021) Update of P2X receptor properties and their pharmacology: IUPHAR Review 30. Br J Pharmacol 178(3):489\u2013514. https:\/\/doi.org\/10.1111\/bph.15299","journal-title":"Br J Pharmacol"},{"issue":"3","key":"9941_CR19","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1124\/pr.112.005983","volume":"64","author":"E van der Pol","year":"2012","unstructured":"van der Pol E, Boing AN, Harrison P, Sturk A, Nieuwland R (2012) Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol Rev 64(3):676\u2013705. https:\/\/doi.org\/10.1124\/pr.112.005983","journal-title":"Pharmacol Rev"}],"container-title":["Purinergic Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-023-09941-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11302-023-09941-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-023-09941-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T05:11:51Z","timestamp":1706677911000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11302-023-09941-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["9941"],"URL":"https:\/\/doi.org\/10.1007\/s11302-023-09941-2","relation":{},"ISSN":["1573-9538","1573-9546"],"issn-type":[{"value":"1573-9538","type":"print"},{"value":"1573-9546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,19]]},"assertion":[{"value":"31 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"FDV is a member of the Scientific Advisory Board of Biosceptre Ltd. (Australia), a biotech company involved in the development of anti-P2X7 antibodies, and a consultant with Breye Therapeutics ApS (Denmark). The other authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}